Independently, we performed a comprehensive analysis of the influence of PPARγ ligands on antileukemic properties of second- and third-generation TKIs in CML cells, which complement and extend data published by Prost et al. We have shown that addition of pioglitazone to TKIs (dasatinib, nilotinib and ponatinib) significantly decreased clonogenic potential of K-562 cells (Figure 1a, upper panel). The gene discussed is PPARG; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.